Literature DB >> 26915638

False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load.

Oksana Ocheretina1, Erin Byrt2, Marie-Marcelle Mabou3, Gertrude Royal-Mardi3, Yves-Mary Merveille3, Vanessa Rouzier3, Daniel W Fitzgerald2, Jean W Pape4.   

Abstract

We report investigation of 22 TB cases with positive Xpert MTB/RIF result for resistance to Rifampin and "Very Low" MTB detection level. Twelve cases were false positive without rpoB mutations, 2 were false-positives with a silent mutation in rpoB codon T508, and only 10 were true positives.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Developing and high-burden countries; MDR-TB; Molecular diagnostics; Tuberculosis; Xpert MTB/RIF

Mesh：

Substances：

Year:  2016        PMID： 26915638      PMCID： PMC4841693          DOI： 10.1016/j.diagmicrobio.2016.01.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  10 in total

1.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

2.  Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance.

Authors:  Akos Somoskovi; Vanessa Deggim; Diana Ciardo; Guido V Bloemberg
Journal:  J Clin Microbiol       Date:  2013-07-12       Impact factor: 5.948

3.  An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis.

Authors:  Deborah A Williamson; Indira Basu; James Bower; Joshua T Freeman; Gillian Henderson; Sally A Roberts
Journal:  Diagn Microbiol Infect Dis       Date:  2012-07-20       Impact factor: 2.803

4.  Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis.

Authors:  Syed Beenish Rufai; Parveen Kumar; Amit Singh; Suneel Prajapati; Veena Balooni; Sarman Singh
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

Review 5.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

6.  Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis.

Authors:  D A Williamson; S A Roberts; J E Bower; R Vaughan; S Newton; O Lowe; C A Lewis; J T Freeman
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

7.  Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression.

Authors:  Colleen F Hanrahan; Grant Theron; Jean Bassett; Keertan Dheda; Lesley Scott; Wendy Stevens; Ian Sanne; Annelies Van Rie
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

8.  Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes.

Authors:  Nicola M Zetola; Sanghyuk S Shin; Kefentse A Tumedi; Keletso Moeti; Ronald Ncube; Mark Nicol; Ronald G Collman; Jeffrey D Klausner; Chawangwa Modongo
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

9.  False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications.

Authors:  A Van Rie; K Mellet; M-A John; L Scott; L Page-Shipp; H Dansey; T Victor; R Warren
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

10.  Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results.

Authors:  Oksana Ocheretina; Vincent E Escuyer; Marie-Marcelle Mabou; Gertrude Royal-Mardi; Sean Collins; Stalz C Vilbrun; Jean W Pape; Daniel W Fitzgerald
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240
  10 in total
  18 in total

1.  On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex.

Authors:  Claudio U Köser; Sophia B Georghiou; Thomas Schön; Max Salfinger
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

2.  Retrospective Analysis of False-Positive and Disputed Rifampin Resistance Xpert MTB/RIF Assay Results in Clinical Samples from a Referral Hospital in Hunan, China.

Authors:  Peilei Hu; Hongtai Zhang; Joy Fleming; Guofeng Zhu; Shuai Zhang; Yaguo Wang; Fengping Liu; Songlin Yi; Zhongnan Chen; Zhenhua Chen; Binbin Liu; Daofang Gong; Li Wan; Xingyun Wang; Yunhong Tan; Liqiong Bai; Lijun Bi
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

3.  Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay.

Authors:  R H Berhanu; K Schnippel; R Kularatne; C Firnhaber; K R Jacobson; C R Horsburgh; C K Lippincott
Journal:  Int J Tuberc Lung Dis       Date:  2019-03-01       Impact factor: 2.373

4.  Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?

Authors:  R H Berhanu; K Schnippel; R Kularatne; C Firnhaber; K R Jacobson; C R Horsburgh; C K Lippincott
Journal:  Int J Tuberc Lung Dis       Date:  2018-08-01       Impact factor: 2.373

5.  Blood transcriptomic markers of Mycobacterium tuberculosis load in sputum.

Authors:  K M Dupnik; J M Bean; M H Lee; M A Jean Juste; L Skrabanek; V Rivera; C K Vorkas; J W Pape; D W Fitzgerald; M Glickman
Journal:  Int J Tuberc Lung Dis       Date:  2018-08-01       Impact factor: 2.373

6.  [Performance of GeneXpert MTB / RIF® in the diagnosis of extrapulmonary tuberculosis in Dakar: 2010-2015].

Authors:  Awa Ba Diallo; Abdoulkader Issifi Kollo; Makhtar Camara; Seynabou Lo; Gedeon Walbang Ossoga; Moustapha Mbow; Farba Karam; Mame Yacine Fall Niang; Aliou Thiam; Awa Ndiaye Diawara; Souleymane Mboup; Aissatou Gaye Diallo
Journal:  Pan Afr Med J       Date:  2016-11-02

7.  Validation of the FluoroType MTBDR Assay for Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Complex Isolates.

Authors:  Doris Hillemann; Carsten Haasis; Sönke Andres; Tobias Behn; Katharina Kranzer
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

8.  Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda.

Authors:  Willy Ssengooba; Jean de Dieu Iragena; Kevin Komakech; Iginitius Okello; Joanitah Nalunjogi; Winceslaus Katagira; Ivan Kimuli; Susan Adakun; Moses L Joloba; Gabriela Torrea; Bruce J Kirenga
Journal:  Open Forum Infect Dis       Date:  2021-04-02       Impact factor: 3.835

9.  Challenges in the diagnosis of tuberculous meningitis.

Authors:  Carlo Foppiano Palacios; Paul G Saleeb
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-05-11

10.  Dependence of Xpert MTB/RIF Accuracy for Detecting Rifampin Resistance in Bronchoalveolar Lavage Fluid on Bacterial Load: A Retrospective Study in Beijing, China.

Authors:  Lin Qin; Fengmin Huo; Weicong Ren; Yuanyuan Shang; Cong Yao; Xuxia Zhang; Rongmei Liu; Liping Ma; Mengqiu Gao; Yu Pang
Journal:  Infect Drug Resist       Date:  2021-06-28       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.